Drugs / KB801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06999733 | Jul 2025 → Dec 2026 expected | neurotrophic keratopathy | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06999733 ↗ |
| Route | Topical | “KB801 or placebo (vehicle) topically” NCT06999733 ↗ |